Skip to main content
NASDAQ:CLDX

Celldex Therapeutics Competitors

$27.09
+2.08 (+8.32 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.01
$27.11
50-Day Range
$19.73
$31.44
52-Week Range
$2.23
$33.24
Volume302,590 shs
Average Volume645,851 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.96

Competitors

Celldex Therapeutics (NASDAQ:CLDX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying CLDX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Celldex Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Celldex Therapeutics (NASDAQ:CLDX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility & Risk

Celldex Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Celldex Therapeutics and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celldex Therapeutics00303.00
Amgen291402.48

Celldex Therapeutics presently has a consensus price target of $35.50, suggesting a potential upside of 31.04%. Amgen has a consensus price target of $255.6190, suggesting a potential upside of 1.69%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Amgen.

Profitability

This table compares Celldex Therapeutics and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celldex Therapeutics-1,069.42%-30.93%-26.55%
Amgen29.42%95.55%15.52%

Insider & Institutional Ownership

80.2% of Celldex Therapeutics shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 2.4% of Celldex Therapeutics shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Celldex Therapeutics and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26
Amgen$23.36 billion6.18$7.84 billion$14.8216.96

Amgen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Celldex Therapeutics on 8 of the 14 factors compared between the two stocks.

Celldex Therapeutics (NASDAQ:CLDX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Celldex Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Celldex Therapeutics and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celldex Therapeutics00303.00
Gilead Sciences091202.57

Celldex Therapeutics presently has a consensus price target of $35.50, indicating a potential upside of 31.04%. Gilead Sciences has a consensus price target of $100.5909, indicating a potential upside of 46.78%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Celldex Therapeutics.

Profitability

This table compares Celldex Therapeutics and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celldex Therapeutics-1,069.42%-30.93%-26.55%
Gilead Sciences5.48%37.77%12.76%

Insider and Institutional Ownership

80.2% of Celldex Therapeutics shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 2.4% of Celldex Therapeutics shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Celldex Therapeutics and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26
Gilead Sciences$22.45 billion3.83$5.39 billion$6.1411.16

Gilead Sciences has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

Celldex Therapeutics (NASDAQ:CLDX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Celldex Therapeutics and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celldex Therapeutics00303.00
Vertex Pharmaceuticals041612.86

Celldex Therapeutics presently has a consensus price target of $35.50, indicating a potential upside of 31.04%. Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 35.19%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Celldex Therapeutics.

Volatility & Risk

Celldex Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Celldex Therapeutics and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celldex Therapeutics-1,069.42%-30.93%-26.55%
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings & Valuation

This table compares Celldex Therapeutics and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26
Vertex Pharmaceuticals$4.16 billion13.50$1.18 billion$4.2950.60

Vertex Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.2% of Celldex Therapeutics shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 2.4% of Celldex Therapeutics shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Regeneron Pharmaceuticals and Celldex Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Celldex Therapeutics00303.00

Regeneron Pharmaceuticals presently has a consensus price target of $656.3810, indicating a potential upside of 27.05%. Celldex Therapeutics has a consensus price target of $35.50, indicating a potential upside of 31.04%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Regeneron Pharmaceuticals.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Celldex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Celldex Therapeutics-1,069.42%-30.93%-26.55%

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Celldex Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.04$2.12 billion$21.4724.06
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26

Regeneron Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Celldex Therapeutics shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Risk & Volatility

Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.

Insider and Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 80.2% of Celldex Therapeutics shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 2.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Biogen and Celldex Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen4141202.27
Celldex Therapeutics00303.00

Biogen presently has a consensus price target of $305.5714, indicating a potential upside of 9.05%. Celldex Therapeutics has a consensus price target of $35.50, indicating a potential upside of 31.04%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Biogen.

Profitability

This table compares Biogen and Celldex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Celldex Therapeutics-1,069.42%-30.93%-26.55%

Valuation and Earnings

This table compares Biogen and Celldex Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.93$5.89 billion$33.578.35
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26

Biogen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Celldex Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.68$2.40 billion$9.7417.81
Celldex Therapeutics$3.57 million300.61$-50,880,000.00($3.28)-8.26

Alexion Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500.

Profitability

This table compares Alexion Pharmaceuticals and Celldex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Celldex Therapeutics-1,069.42%-30.93%-26.55%

Analyst Recommendations

This is a summary of current ratings for Alexion Pharmaceuticals and Celldex Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals015402.21
Celldex Therapeutics00303.00

Alexion Pharmaceuticals currently has a consensus target price of $159.3158, indicating a potential downside of 8.17%. Celldex Therapeutics has a consensus target price of $35.50, indicating a potential upside of 31.04%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Alexion Pharmaceuticals.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Celldex Therapeutics shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.


Celldex Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$251.38+0.4%$144.43 billion$23.36 billion20.27Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$68.53+0.6%$85.95 billion$22.45 billion70.65
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$217.09+1.3%$56.20 billion$4.16 billion27.41
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$516.62+0.1%$55.35 billion$7.86 billion18.88Analyst Report
Biogen logo
BIIB
Biogen
1.5$280.21+0.5%$42.19 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$173.49+0.1%$38.34 billion$4.99 billion40.54
Seagen logo
SGEN
Seagen
1.5$147.50+1.9%$26.77 billion$916.71 million58.07Insider Selling
Incyte logo
INCY
Incyte
1.6$82.62+0.7%$18.17 billion$2.16 billion-52.62Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$96.74+3.2%$16.60 billion$876.29 million-43.77Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.70+2.0%$15.95 billion$219.75 million-17.33
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.93+1.8%$14.06 billion$1.70 billion17.60Insider Selling
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
United Therapeutics logo
UTHR
United Therapeutics
1.7$197.87+2.1%$8.86 billion$1.45 billion18.72Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$25.56+0.4%$8.01 billion$967.78 million53.25Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.24+2.3%$5.39 billion$1.12 billion79.67Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.46+1.6%$3.73 billion$806.43 million-8.71Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.26+0.1%$3.57 billion$1.17 billion-48.39Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$62.00+5.6%$3.32 billion$1.11 billion19.94Analyst Report
Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.49+1.3%$2.52 billion$182.24 million-8.25Earnings Announcement
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.70+7.8%$2.48 billion$901.90 million-20.55Insider Buying
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.5$134.70+2.3%$2.23 billionN/A-12.17
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$129.52+4.4%$2.16 billion$120.28 million-130.83
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.38+6.3%$2.11 billion$638.60 million-10.53
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.68+1.7%$1.88 billion$428.41 million16.93
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.75+5.2%$1.35 billion$82.27 million-16.46Earnings Announcement
Analyst Revision
Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.87+0.9%$1.30 billion$261.02 million6.57
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Codexis logo
CDXS
Codexis
1.5$18.29+3.8%$1.18 billion$68.46 million-52.26
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.07 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.65+1.3%$1.04 billion$227.19 million51.81Analyst Report
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.80+6.0%$893.79 million$35.22 million-5.69Analyst Downgrade
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.44+4.5%$728.19 million$36.13 million-15.58Analyst Report
Agenus logo
AGEN
Agenus
1.6$3.23+6.2%$718.48 million$150.05 million-2.96Analyst Upgrade
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+4.4%$683.21 million$150,000.00-4.53Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.79+2.4%$682.60 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.71+2.4%$631.31 million$59.29 million-24.73
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.33+3.0%$625.20 million$322.07 million-4.12Analyst Revision
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87+4.3%$613.80 million$143.01 million-1.12Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$18.15+5.1%$601.89 million$252 million-1.86Analyst Report
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.48+12.1%$541.88 million$109.33 million-2.56Earnings Announcement
News Coverage
Verastem logo
VSTM
Verastem
1.5$2.94+4.8%$505.44 million$17.46 million-2.09Earnings Announcement
Analyst Report
News Coverage
Geron logo
GERN
Geron
1.4$1.43+6.3%$455.55 million$460,000.00-4.09Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.86+6.1%$440.85 million$22.27 million-3.85Earnings Announcement
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.68+1.9%$357.90 million$36.63 million-4.33Upcoming Earnings
XOMA logo
XOMA
XOMA
1.5$29.92+2.1%$337.20 million$18.37 million-26.95
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.